Currently, low concentrations of AMPH (5–30 mg/pill) are successfully used to treat patients affected with narcolepsy, chronic fatigue syndrome and those affected with attention deficit disorders. The gene discussed is AMPH; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.